Go Back to Top
Mundipharma

Ophthalmology

At Mundipharma, we are committed to developing and providing innovative therapeutic solutions that make a true impact on improving the health and quality of life of people everywhere.

Our ophthalmology portfolio consists of a range of well-known products that cover the primary treatment methods for patients with open-angle glaucoma, the most predominant type of glaucoma in the world1.

What is glaucoma?2

Glaucoma refers to a group of disorders that leads to damage of the optic nerve. Glaucoma is often associated with increased eye pressure, although it may occur with normal eye pressure.  It is a slow progressive disease leading to irreversible loss of vision and can result in blindness. If diagnosed and treated early, blindness is preventable.

Prevalence2

Worldwide about 66 million people are affected with glaucoma. 10% of these people become blind due to glaucoma. In South Africa, it is estimated that about 200,000 people are affected.

Who is at risk for glaucoma?3

Some people have a higher than normal risk of getting glaucoma. This includes people who:

Glaucoma treatment3

Glaucoma damage is permanent—it cannot be reversed. But medicine and surgery can help to stop further damage.

References:

  1. Quigley et al. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmology 2006;90:262–267
  2. www.sags.co.za
  3. www.aao.org/eye-health/diseases/what-is-glaucoma
Cosopt Logo

Ophthalmic Solution

View COSOPT®

Timoptol Logo

0,25 % Ophthalmic Solution
0,5 % Ophthalmic Solution

View TIMOPTOL®

Timoptol Xe 0 25 Logo

0,25 % Sterile Ophthalmic
Gellan Solution
0,50 % Sterile Ophthalmic
Gellan Solution

View TIMOPTOL-XE®

Trusopt Logo

2 % Ophthalmic Solution

View TRUSOPT®

Saflutan Logo

Ophthalmic Solution

View SAFLUTAN®